Home/Filings/4/0001818382-22-000200
4//SEC Filing

Sander Dale A. 4

Accession 0001818382-22-000200

CIK 0001818382other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 4:14 PM ET

Size

5.4 KB

Accession

0001818382-22-000200

Insider Transaction Report

Form 4
Period: 2022-12-08
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Transactions
  • Award

    Stock Options (right to buy)

    2022-12-08+136,000136,000 total
    Exercise: $3.07Exp: 2032-12-08Common Stock (136,000 underlying)
Footnotes (1)
  • [F1]The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.

Issuer

Humacyte, Inc.

CIK 0001818382

Entity typeother

Related Parties

1
  • filerCIK 0001878193

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 4:14 PM ET
Size
5.4 KB